Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akcea Therapeutics Inc.

Division of Ionis Pharmaceuticals Inc.
www.akceatx.com

Latest From Akcea Therapeutics Inc.

Akcea Therapeutics Steps Up Commercialization Efforts In Europe

With one rare disease drug already available in Europe, and a second imminent, Akcea’s CEO outlined in a Scrip interview the European plans for this still-youthful US biotech.

Rare Diseases Approvals

EU CHMP Backs Three Conditional Approvals & Several Treatment Firsts

Akcea’s Waylivra, Portola’s Ondexxya, BioMarin’s Palynziq, AbbVie’s Skyrizi and Pfizer’s Lorviqua are among new drugs to receive a positive opinion from the EU’s CHMP at its latest monthly meeting.
Europe Drug Review

Risankizumab, Andexanet Alfa & GSK’s IV Zanamivir Up For CHMP Opinion

Opinions on whether new products for the treatment of conditions such as psoriasis, coagulation reversal, flu and diabetes should be granted an EU marketing authorization are due this week as the EMA’s key scientific committee, the CHMP, meets for the last time in London..
Europe Approvals

Deal Watch: Novartis Opts In On Lipoprotein A Candidate From Akcea

Novartis will take over development and commercialization of antisense candidate TQJ230 under rights it obtained in a 2017 agreement. Morphic and Janssen will collaborate on oral integrin inhibitors.

Business Strategies Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
  • Alias(es)
  • 1662524
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ionis Pharmaceuticals Inc.
  • Senior Management
  • Paula Soteropoulos, CEO
    Michael MacLean, CFO
    Jeffrey M Goldberg , COO
    Louis St. L O’Dea, MD, CMO
    Sarah Boyce, Pres.
  • Contact Info
  • Akcea Therapeutics Inc.
    Phone: (617) 207-0202
    55 Cambridge Parkway
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register